AGRX:NSD-Agile Therapeutics Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 0.60

Change

-0.04 (-5.81)%

Market Cap

USD 0.08B

Volume

2.85M

Avg Analyst Target

USD 3.33 (+455.56%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

Agile Therapeutics Inc (AGRX) Stock Analysis:
Based on the Agile Therapeutics Inc stock forecasts from 3 analysts, the average analyst target price for Agile Therapeutics Inc is USD 3.33 over the next 12 months. Agile Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Agile Therapeutics Inc is Very Bearish, which is based on 0 positive signals and 5 negative signals. At the last closing, Agile Therapeutics Inc’s stock price was USD 0.60. Agile Therapeutics Inc’s stock price has changed by +0.00 % over the past week, -0.26 % over the past month and -79.17 % over the last year.

About

Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch. The company is ...Read More

Company Website : http://www.agiletherapeutics.com

Address : 101 Poor Farm Road, Princeton, NJ, United States, 08540

Employees : 28

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 0.93

52 Week High : 3.77

Short Ratio : 0.59

52 Week Low : 0.54

Shorted Shares : 1,443,107

200 Day Moving Average : 1.41

Shorted Shares Previous Month : 1,626,710

50 Day Moving Average : 0.80

Shares Held By Insiders : 1.10%

Short Percentage : 1.00%

Shares Held by Institutions : 34.61%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-12-02 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MYL Mylan N.V

N/A

 USD8.59B 30.73 11.86
NBIX Neurocrine Biosciences Inc

-0.15 (-0.19%)

 USD8.04B 17.79 39.74
APHA Tilray, Inc

N/A

 USD6.86B 60.60 454.68
MNTA Momenta Pharmaceuticals, Inc

N/A

 USD6.24B N/A N/A
TLRY Tilray Inc

+0.27 (+2.91%)

 USD4.69B N/A N/A
CGC Canopy Growth Corporation

+0.42 (+4.23%)

 USD4.22B N/A N/A
ITCI Intra-Cellular Therapies Inc

+0.08 (+0.21%)

 USD3.33B N/A N/A
PCRX Pacira BioSciences Inc

+0.46 (+0.86%)

 USD2.28B 39.33 17.58
DVAX Dynavax Technologies Corporati..

-0.41 (-2.71%)

 USD1.93B N/A 98.57
IRWD Ironwood Pharmaceuticals Inc

+0.17 (+1.55%)

 USD1.78B 3.37 7.24

ETFs Containing AGRX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -79.09% 5% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -79.09% 5% F 3% F
Trailing 12 Months  
Capital Gain -79.17% 5% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -79.17% 5% F 2% F
Trailing 5 Years  
Capital Gain -91.12% 14% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -91.12% 14% F 4% F
Average Annual (5 Year Horizon)  
Capital Gain 34.69% 81% B- 78% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 34.69% 81% B- 78% C+
Risk Return Profile  
Volatility (Standard Deviation) 120.90% 16% F 13% F
Risk Adjusted Return 28.69% 68% D+ 42% F
Market Capitalization 0.08B 23% F 18% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 7.16 16% F 18% F
Price / Cash Flow Ratio -1.62 36% F 57% F
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -180.07% 17% F 14% F
Return on Invested Capital -87.89% 17% F 9% F
Return on Assets -64.82% 4% F 3% F
Debt to Equity Ratio 33.21% 46% F 48% F
Technical Ratios  
Short Ratio 0.59 88% B+ 83% B
Short Percent 1.39% 91% A- 66% D
Beta 0.93 63% D 62% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.